CAG
CMD

Csenge Advisory Group’s Cantel Medical Corporation CMD Stock Holding History

Csenge Advisory Group’s Portfolio CMD Stock Details CMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-341
Closed -$28K – 1699
2018
Q3 		$28K Buy
+341
New +$32.5K 0.01% 345

Other funds holding CMD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
DM
Diker Management New York $112M AUM 59.78% 1-Year Est. Return
CCA
Conestoga Capital Advisors Wayne, Pennsylvania $5.01B AUM 6.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CIP
Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return

Csenge Advisory Group's CMD Position: Q4 2018 in Review

Csenge Advisory Group sold out of Cantel Medical Corporation (CMD) in Q4 2018, closing a stake of 341 shares — an estimated $28K sold.

Csenge Advisory Group first reported a position in CMD in Q3 2018 and held it in 1 quarter. The position peaked at $28K in Q3 2018. 253 funds tracked by Wall St. Rank hold CMD as of Q4 2018.

  • Csenge Advisory Group reported no remaining Cantel Medical Corporation position as of Q4 2018 after selling out during the quarter.
  • Csenge Advisory Group sold 341 Cantel Medical Corporation shares in Q4 2018, an estimated $28K.
  • Csenge Advisory Group first reported a position in Cantel Medical Corporation in Q3 2018 and held it in 1 quarter.
  • Csenge Advisory Group's Cantel Medical Corporation position peaked at $28K in Q3 2018.
  • 253 funds tracked by Wall St. Rank held Cantel Medical Corporation as of Q4 2018.

Based on Csenge Advisory Group's 13F filing for Q4 2018, filed 7 Feb 2019.